Skip to content

ReguSAMe

Innovative mRNA Therapeutics

Treating liver cirrhosis by regulating intracellular SAM concentration through a negative feedback mechanism

Cirrhosis is a chronic progressive liver disease that poses a major health burden worldwide. It is the third leading cause of death among people aged 45 to 64.
0
Incidence globally per year
0
Deaths globally per year

Liver-protective therapy delays the progression of liver cirrhosis through mechanisms such as antioxidation, anti-inflammation, and the promotion of hepatocyte repair. S-adenosyl-L-methionine (SAM) is a common liver supplement and serves as an important adjunctive therapy.

The clinical practice has confirmed that exogenous SAM supplementation can, to some extent, delay the progression of liver disease. However, existing supplementation therapies still have significant limitations.

problem-fot-direct-administration-of-same

Our Goal

ReguSAMe

We aim to achieve negative feedback Regulation of intracellular SAM concentration by an RNA element.

Our Solution

We developed an mRNA drug that carries the MAT1A ORF encoding MATI enzyme and incorporated the SAM-responsive aptazyme in its 3' UTR. The MAT I enzyme catalyzes the synthesis of SAM.

Our Solution - mRNA drug with MAT1A ORF and SAM-responsive aptazyme
Mechanism Section

ReguSAMe Project Overview

ReguSAMe Project Overview
Wet Lab

Wet Lab

We went through several experimental cycles in our wet experiments before fully developing ReguSAMe. Specifically, we selected ribozymes and SAM riboswitches, modified aptazymes, constructed liver cirrhosis cell models, and verified the cutting efficiency. Ultimately, we have developed an mRNA-based liver cirrhosis treatment method based on ReguSAMe.

Dry Lab

Dry Lab

Our dry-lab team leverages advanced computational models and custom software platforms for RNA design and analysis. From secondary structure prediction to small molecule binding and RNA-protein interaction simulations, our tools provide efficient and reliable guidance for experimental validation, accelerating the overall research process.

Human Practice

Human Practice

The achievements of HP focus on inclusivity, IHP, and collaboration.In terms of inclusivity, we have carried out various activities and written the "Inclusivity Guide." Regarding IHP, we approached from three aspects: wet lab, dry lab, and HP, to communicate with stakeholders. In the area of collaboration, we co-hosted this year's CCiC and participated in many conferences for exchange. The three aspects are advanced in parallel, jointly promoting the implementation and realization of the project.

Start Explore!

Learn more noteworthy details about ReguSAMe from our Wiki page.